These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16222146)

  • 1. Chemo-inducible gene therapy.
    Mezhir JJ; Schmidt H; Yamini B; Senzer NN; Posner MC; Kufe DW; Weichselbaum RR
    Anticancer Drugs; 2005 Nov; 16(10):1053-8. PubMed ID: 16222146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ionizing radiation: a genetic switch for cancer therapy.
    Mezhir JJ; Smith KD; Posner MC; Senzer N; Yamini B; Kufe DW; Weichselbaum RR
    Cancer Gene Ther; 2006 Jan; 13(1):1-6. PubMed ID: 16082378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How is gene transfection able to improve current chemotherapy? The role of combined therapy in cancer treatment.
    Prados J; Alvarez PJ; Melguizo C; Rodriguez-Serrano F; Carrillo E; Boulaiz H; Vélez C; Marchal JA; Caba O; Ortiz R; Rama A; Aranega A
    Curr Med Chem; 2012; 19(12):1870-88. PubMed ID: 22414080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.
    Robson T; Worthington J; McKeown SR; Hirst DG
    Technol Cancer Res Treat; 2005 Aug; 4(4):343-61. PubMed ID: 16029055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy.
    Walther W; Wendt J; Stein U
    Gene Ther; 1997 Jun; 4(6):544-52. PubMed ID: 9231070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors.
    Walther W; Stein U; Fichtner I; Alexander M; Shoemaker RH; Schlag PM
    Cancer Gene Ther; 2000 Jun; 7(6):893-900. PubMed ID: 10880020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-specific gene therapy.
    Lo HW; Day CP; Hung MC
    Adv Genet; 2005; 54():235-55. PubMed ID: 16096014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy strategies to improve the effectiveness of cancer radiotherapy.
    Freytag SO; Kim JH; Brown SL; Barton K; Lu M; Chung M
    Expert Opin Biol Ther; 2004 Nov; 4(11):1757-70. PubMed ID: 15500404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for enhancing viral-based gene therapy using ionizing radiation.
    Chmura SJ; Advani SJ; Kufe DW; Weichselbaum RR
    Radiat Oncol Investig; 1999; 7(5):261-9. PubMed ID: 10580895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional gene targeting for cancer gene therapy.
    Haviv YS; Curiel DT
    Adv Drug Deliv Rev; 2001 Dec; 53(2):135-54. PubMed ID: 11731024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.
    Sipo I; Hurtado Picó A; Wang X; Eberle J; Petersen I; Weger S; Poller W; Fechner H
    J Mol Med (Berl); 2006 Mar; 84(3):215-25. PubMed ID: 16437213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.
    Quiñones A; Dobberstein KU; Rainov NG
    Life Sci; 2003 May; 72(26):2975-92. PubMed ID: 12706485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach.
    Jiang G; Xin Y; Zheng JN; Liu YQ
    Int J Cancer; 2011 Jul; 129(2):263-74. PubMed ID: 21509783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional control of viral gene therapy by cisplatin.
    Park JO; Lopez CA; Gupta VK; Brown CK; Mauceri HJ; Darga TE; Manan A; Hellman S; Posner MC; Kufe DW; Weichselbaum RR
    J Clin Invest; 2002 Aug; 110(3):403-10. PubMed ID: 12163460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
    Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
    Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents.
    Mantwill K; Köhler-Vargas N; Bernshausen A; Bieler A; Lage H; Kaszubiak A; Surowiak P; Dravits T; Treiber U; Hartung R; Gansbacher B; Holm PS
    Cancer Res; 2006 Jul; 66(14):7195-202. PubMed ID: 16849566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies.
    Kuwano M; Uchiumi T; Hayakawa H; Ono M; Wada M; Izumi H; Kohno K
    Cancer Sci; 2003 Jan; 94(1):9-14. PubMed ID: 12708467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.
    Weichselbaum RR; Kufe D
    Cancer Gene Ther; 2009 Aug; 16(8):609-19. PubMed ID: 19444302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation.
    Kawashita Y; Ohtsuru A; Kaneda Y; Nagayama Y; Kawazoe Y; Eguchi S; Kuroda H; Fujioka H; Ito M; Kanematsu T; Yamashita S
    Hum Gene Ther; 1999 Jun; 10(9):1509-19. PubMed ID: 10395376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 gene replacement for cancer--interactions with DNA damaging agents.
    Roth JA; Grammer SF; Swisher SG; Komaki R; Nemunaitis J; Merritt J; Meyn RE
    Acta Oncol; 2001; 40(6):739-44. PubMed ID: 11765069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.